-- Financing oversubscribed; proceeds from the round will be used to expand Strand’s growing mRNA platforms into multiple immuno-oncology and disease settings, and advance lead drug into Phase 1 ...
Strand Therapeutics, a leader in next-generation mRNA-based therapeutics, today announced the promotion of Prashant Nambiar, DVM, PhD, MBA, as Chief Scientific Officer and appointment of Ethan Cash as ...
Leader in mRNA therapeutics strengthens clinical development expertise with globally recognized oncology innovator Strand Therapeutics, the leader in programmable mRNA medicines, today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback